Avalo TherapeuticsAVTX
Market Cap: $7.82M
About: Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Employees: 19
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
52% more capital invested
Capital invested by funds: $1.9M [Q1] → $2.89M (+$994K) [Q2]
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
11.58% more ownership
Funds ownership: 10.94% [Q1] → 22.53% (+11.58%) [Q2]
11% more funds holding
Funds holding: 18 [Q1] → 20 (+2) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for AVTX.